Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Sysco Q2 Profit Down - Quick Facts

RELATED NEWS
Trade SYY now with 

Sysco Corp. (SYY: Quote) reported that its second-quarter net earnings declined to $250.11 million or $0.43 per share, from $258.17 million or $0.44 per share in the same quarter last year. However, Non-GAAP net income rose to $0.46 per share from $0.45 per share in the year ago quarter.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.44 per share for the quarter. Analysts' estimates typically exclude special items.

Sales for the quarter rose to $10.24 billion from $9.38 billion in the prior year quarter. Nine analysts had consensus revenue estimate of $10.04 billion for the quarter.

Click here to receive FREE breaking news email alerts for Sysco Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.